http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2856348-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2848 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2015-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce1a560d9ea7c5dac2f70a0b4828812a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c684b71bd14e90542453b2e5bd99817c |
| publicationDate | 2021-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2856348-T3 |
| titleOfInvention | A method for the treatment of solid cancers and / or metastases thereof, related drugs, and a method for the prediction of the clinical evolution of the treatment of solid cancers and / or metastases thereof |
| abstract | Abituzumab for use in the treatment of colorectal cancer (CRC) and / or metastases thereof in a subject, wherein said subject is characterized by a) high levels of one or more proteins in at least one body fluid of said subject , wherein said one or more proteins comprise: TPO (UniProt ID: P07202), and optionally b) low levels of a protein in at least one body fluid of said subject, wherein said protein is: TGM3 (UniProt ID: Q08188); and wherein said abituzumab is administered to said subject, wherein the level of said protein in at least one body fluid of said subject a) is classified as high, if the level of the corresponding protein in said body fluid is at least 2% higher than the median threshold determined for the corresponding protein, and b) is classified as low, if the level of the corresponding protein in said body fluid is at least 2% lower, more preferably at least 5% lower, even more preferably at least 10% lower and especially at least 25% lower than said threshold median for the corresponding protein. |
| priorityDate | 2014-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 275.